Were Analysts Bullish Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) This Week?

April 17, 2018 - By Dolores Ford

Investors sentiment decreased to 1.62 in Q4 2017. Its down 1.51, from 3.13 in 2017Q3. It turned negative, as 5 investors sold Aldeyra Therapeutics, Inc. shares while 8 reduced holdings. 9 funds opened positions while 12 raised stakes. 9.98 million shares or 45.35% less from 18.26 million shares in 2017Q3 were reported.
715,679 are held by Millennium Mgmt Ltd Liability Corp. State Street Corp invested 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Drw Limited Liability Com holds 0.01% or 12,000 shares. Fmr Ltd Liability holds 0% or 1.61M shares. Dimensional Fund Advsr L P owns 50,923 shares or 0% of their US portfolio. Alphaone Inv Services Limited Company stated it has 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Mangrove Prtn has 164,384 shares. Sphera Funds Mngmt Ltd has invested 0.83% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Jpmorgan Chase And Com invested in 49,676 shares. Wells Fargo Co Mn reported 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Weiss Multi invested 0.01% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). 693,000 are owned by Adage Cap Prtn Gp Limited Liability Company. Private Ocean Limited Com reported 1,000 shares stake. Acadian Asset Mngmt Ltd Llc holds 0% or 5,534 shares in its portfolio. Macquarie Ltd invested 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX).

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 2 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics had 4 analyst reports since October 24, 2017 according to SRatingsIntel. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, November 9. Cantor Fitzgerald initiated the shares of ALDX in report on Tuesday, October 24 with “Buy” rating. Cantor Fitzgerald maintained Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) on Thursday, March 29 with “Buy” rating. Below is a list of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) latest ratings and price target changes.

29/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $23.0000 Maintain
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $13 Initiates Coverage On
09/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $22.0 Maintain
24/10/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $22.0 Initiate

The stock increased 3.21% or $0.22 during the last trading session, reaching $7.22. About 46,456 shares traded. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 55.45% since April 17, 2017 and is uptrending. It has outperformed by 43.90% the S&P500.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $142.08 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjgren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: